TW592716B - Minoxidil-containing liquid composition - Google Patents
Minoxidil-containing liquid composition Download PDFInfo
- Publication number
- TW592716B TW592716B TW088108677A TW88108677A TW592716B TW 592716 B TW592716 B TW 592716B TW 088108677 A TW088108677 A TW 088108677A TW 88108677 A TW88108677 A TW 88108677A TW 592716 B TW592716 B TW 592716B
- Authority
- TW
- Taiwan
- Prior art keywords
- liquid composition
- amino acid
- minoxidil
- patent application
- liquid
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 238000004040 coloring Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 230000003779 hair growth Effects 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000012669 liquid formulation Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Description
經濟部智慧財產局員工消費合作社印製 592716 A7 _____ B7 五、發明說明(1 ) 本發明關於一種含敏諾稀迪之液體組成物;其會防止 隨時間之著色。 背景技術 敏諾稀迪因具有生髮效果,故是一種作爲外用生髮劑 之成份。 然而’虽以液悲儲存時’敏諾稀迪具有一種隨時間而 著色之傾向的缺點,因此導致商品價値的減低。含敏諾稀 迪之液體製劑的著色機轉無須明瞭,但假設是因光引起的 。因此’需要使用遮光容器以使含敏諾稀迪之液體製劑商 品化。然而,這些容器不方便使用,因例如容器中之剩餘 量並不淸楚。 通常,含有此種易於著色之成份的液體製劑在一種與 抗氧化劑或抗螯合劑之組合物中會改良,但是,此一組合 物在防止含敏諾稀迪之液體製劑隨時間之著色方面的效果 並不夠。 另一方面,當一製劑著色時,A防止色彩之顯著性, 想要使製劑先被著色。然而,因爲生髮製劑藉應用至頭皮 上而使用,先被著色之製劑會因沾污衣物或寢具而令人不 悅。 發明揭示 由於爲要防止含敏諾稀迪之液體製劑著色的各種硏究 ,本發明人已經發現:含敏諾稀迪之液體製劑藉著與胺基 本纸張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------訂---------線一 (請先閱讀背面之注意事項寫本頁) 經濟部智慧財產局員工消費合作社印製 592716 A7 B7 五、發明說明(2 ) 酸,特別地牛磺酸結合可以令人驚訝地防止著色,藉此已 完成本發明。 亦即,本發明關於一種含有敏諾稀迪及胺基酸之液體 組成物。 依本發明,胺基酸係指任何可以含於外用液體製劑之 胺基酸,且包括其鹽類。 在本發明之胺基酸中’鑑於防止著色之效果’有利者 是含硫之胺基酸(如牛磺酸、半胱胺酸、胱胺酸、甲硫胺 酸或高半胱胺酸),特別是牛磺酸。 在本發明之液體組成物中’敏諾稀迪之有利濃度基於 液體製劑是0 · 1至5 W t %。若少於0 · 1 W t %,則 敏諾稀迪之生髮效果是弱的,且若大於5 w t % ’則難以 設計此製劑。 依本發明,胺基酸之量愈高’會預期液體製劑有愈高 之防止著色效果,但胺基酸之有利量是每1重量份敏諾稀 迪〇·01至20重量份。 在本發明之液體組成物中的有利的製備溶劑是含水的 有機溶劑,因胺基酸無法僅溶於有機溶劑中’而敏諾稀迪 無法僅溶於水中。水含量有利的是自1 0至5 V / V %。 在本文中所用之有機溶劑需能均勻地與水混合且當作爲皮 膚外用製劑時不會對皮膚有不良影響。鑑於此’有機溶劑 之有利實例是具有1至6碳原子之醇(如乙醇、丙醇、異 丙醇、乙二醇、丙二醇、1 ,3 - 丁二醇、甘油等)’且 特別有利的溶劑是擇自由乙醇、丙一醇及1 ’ 3 一丁 一醇 _本紙張尺度適用中國國豕標準(CNS)A4規格(210 X 297公釐Γ Γ5. --------^--------- (請先閱讀背面之注意事項寫本頁) 592716 Α7 Β7 五、發明說明(3 ) 所組成之群中的一或多者。 依本發明,鑑於著色之防止,當用純化的水稀釋至 2 0倍時,此液體製劑有利地調至ρ η 4 - 9。 本發明使得供含敏諾稀迪之液體組成物用的儲存容器 可能從任何供普通液體製劑所用之容器中選擇,但有利的 容器材料是PET、玻璃、聚乙烯、聚丙烯等。 本發明之液體製劑可以藉一種產製液體製劑之普通方 法末產製’但晶|女基酸被結合時,有利的是一種方法,其 中預先溶於水中之胺基酸的溶液混以一有機溶劑,因鑑於 胺基酸之溶解速率,稍後要將胺基酸溶於含水有機溶劑中 要化長的時間。 本發明之液體製劑可以含有任何一般用於外用液體製 劑的成份(如增溶劑、增稠劑、吸收加速劑、ρ Η調節劑 等)。 依本發明,對製劑著色之防止效果藉與胺基酸的結合 而確認’且進一步同時賦與胺基酸原有之醫藥效果(消炎 作用’皮膚刺激之減低作用,止癢作用等)。 實施本發明之最佳模式 藉以下實例及實驗更詳細地說明本發明。 實例1 1克敏諾稀迪,0 · 04克牛磺酸,10克丙二醇, 6 0克乙醇及會補足至1 0 0毫升之總體積用的純水在攪 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) C請先閱讀背面之注意事項寫本頁)
--------訂---------線I 經濟部智慧財產局員工消費合作社印製 6 A7 B7 L '發明說明(4 ) 溶解,藉此得到一液體製劑 比較性實例1 除了牛擴酸以外’使用相同配方,遵循如實例1中之 牛目同程序,得到一比較性液體製劑。 貫驗1 在實例1及比較性實例1中所得之液體製劑各自置入 3個透明玻璃瓶中,且在室溫下照射30〇〇1之光 3 4天。在實驗開始及結束時測量在4 2 0 n m波長及 1 c m管長度下之吸光度。結果顯示於表1中。 請 先 閱 讀 背 面 之 注 意 事 項
I.裝 頁I I I I I I訂 經濟部智慧財產局員工消費合作社印制< 表 實例1 比較性實例1 測試藥 1 測試藥 2 測試藥 3 測試藥 1 測試藥 2 測試藥 3 在實驗開 0.002 0.002 0.002 0.001 0.001 0.001 始時 在實驗結 0.056 0.050 0.058 0.090 0.077 0.097 束時 實例2 1克敏諾稀迪,0 · 1克牛磺酸,10克丙二醇, 6 0克乙醇及會補足至1 0 0毫升之總體積用的純水在攪 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 592716 A7 ----- B7 五、發明說明(5 ) # T被溶解,藉此得到一液體製劑 實驗2 在實例2及比較性實例1中所得之液體製劑各自置於 一無色玻璃瓶中,且使之靜置在室溫下窗戶旁以接收陽光 6個月。在3 〇天及6個月後,3位不知液體製劑內容之 胃i查員巨觀地判斷著色。再者,在實驗開始及6個月後測 量在4 2 〇 n m波長,1 cm管長度下之吸光度。結果示 於表2中。 請 先 閱 讀 背 面 之 注 意 事 項 表2 實例2 顏色 吸光度 比較性實例1 顏色 吸光度 開始時 4E色 0.002 ΛΕ色 j\\\ 匕^ 0.002 30天 ΛΕ色 /\\\ — 淡黃色 — 6個月 淡黃色 0.152 深黃色 0.508 I裝 頁I w I I I I I I訂 I I線 經濟部智慧財產局員工消費合作社印製 工業應用性 本發明使含敏諾稀迪之液體製劑可能免於著色’且因 此可以用來作爲商業上優良之生髮製劑。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -8-
Claims (1)
- 592716A8 B8 C8 D8 六、申請專利範圍 第8 8 1 0867 7號專利申請案 中文申請專利範圍修正本 (請先閲讀背面之注意事項再填寫本頁) 民國93年2月6日修正 1 · 一種用於促進毛髮生長之含敏諾稀迪(minoxidil )之液體組成物,其含有敏諾稀迪及含硫的胺基酸。 2 ·如申請專利範圍第1項之液體組成物,其中胺基 酸是牛磺酸。 3 ·如申請專利範圍第1項之液體組成物,其中胺基 酸的量是每1重量份敏諾稀迪自0 . 0 1至2 0重量份。 4 ·如申請專利範圍第1至3項中任一項之液體組成 物,其中欲使用之溶劑是水及具1至6個碳原子之醇的混 合物而混合物中之水的含量是1 0至5 0 v/v%,及該 具1至6個碳原子之醇是選自乙醇、丙醇、異丙醇、乙二 醇、丙二醇、1 ,3 -丁二醇和甘油。 5 ·如申請專利範圍第4項之液體組成物,其中具1 至6個碳原子之醇是選自乙醇、丙二醇及1 ,3 — 丁二醇 〇 6 ·如申請專利範圍第1至3項中任一項之液體組成 經濟部智慧財產局員工消費合作社印製 物,其中敏諾稀迪之量係佔整個製劑的0 · 1至5 w t % 〇 7 · —種防止含敏諾稀迪之液體組成物著色之試劑, 其含有含硫的胺基酸作爲有效成份。 8 · —種防止含敏諾稀迪之液體組成物著色的方法, 其包括添加一含硫的胺基酸。 本&尺度適用中國國家標準(CNS ) A4規格(210X297公H ^ 一
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33306097 | 1997-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW592716B true TW592716B (en) | 2004-06-21 |
Family
ID=18261827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088108677A TW592716B (en) | 1997-12-03 | 1999-05-26 | Minoxidil-containing liquid composition |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1050310A1 (zh) |
JP (1) | JP4390030B2 (zh) |
KR (1) | KR20010032724A (zh) |
CN (1) | CN1280507A (zh) |
AU (1) | AU736407B2 (zh) |
BR (1) | BR9815347A (zh) |
CA (1) | CA2311731A1 (zh) |
ID (1) | ID24902A (zh) |
NO (1) | NO20002797L (zh) |
NZ (1) | NZ504825A (zh) |
TW (1) | TW592716B (zh) |
WO (1) | WO1999027966A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4610040B2 (ja) | 2000-04-04 | 2011-01-12 | 東レ・ダウコーニング株式会社 | 育毛剤用添加剤及び育毛剤組成物 |
ATE368463T1 (de) * | 2001-05-15 | 2007-08-15 | Taisho Pharmaceutical Co Ltd | Minoxidil-enthaltende flüssige zusammensetzung |
KR100943309B1 (ko) * | 2001-06-14 | 2010-02-23 | 오츠카 세이야쿠 가부시키가이샤 | 의약 조성물 |
JP2005075735A (ja) * | 2003-08-28 | 2005-03-24 | Rohto Pharmaceut Co Ltd | オキシメタゾリン含有組成物 |
JP6261874B2 (ja) * | 2013-04-24 | 2018-01-17 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
JP6244101B2 (ja) * | 2013-04-24 | 2017-12-06 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
JP2017210480A (ja) * | 2017-08-07 | 2017-11-30 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
JP2017226692A (ja) * | 2017-09-05 | 2017-12-28 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
JP2018199738A (ja) * | 2018-10-02 | 2018-12-20 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
JP2018199739A (ja) * | 2018-10-02 | 2018-12-20 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
CN109431996B (zh) * | 2018-12-28 | 2021-09-10 | 浙江万晟药业有限公司 | 一种含米诺地尔的外用剂组合物及其制备方法 |
JP2020189883A (ja) * | 2020-08-24 | 2020-11-26 | ロート製薬株式会社 | ミノキシジル含有外用組成物 |
BR102021003531A2 (pt) | 2021-02-24 | 2022-08-30 | Eurofarma Laboratorios S.A. | Composição farmacêutica tópica espumável |
CN115501178B (zh) * | 2022-08-26 | 2023-05-19 | 山东京卫制药有限公司 | 含有米诺地尔的稳定的液体组合物及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5235729B2 (zh) * | 1973-02-12 | 1977-09-10 | ||
JPS5195120A (en) * | 1975-02-10 | 1976-08-20 | Tenganekino seizoho | |
JPS5888306A (ja) * | 1981-11-19 | 1983-05-26 | Takeo Kinji | 養毛化粧料 |
-
1998
- 1998-12-02 AU AU13507/99A patent/AU736407B2/en not_active Ceased
- 1998-12-02 CN CN98811791A patent/CN1280507A/zh active Pending
- 1998-12-02 WO PCT/JP1998/005446 patent/WO1999027966A1/ja not_active Application Discontinuation
- 1998-12-02 BR BR9815347-1A patent/BR9815347A/pt not_active IP Right Cessation
- 1998-12-02 KR KR1020007006013A patent/KR20010032724A/ko not_active Application Discontinuation
- 1998-12-02 NZ NZ504825A patent/NZ504825A/en unknown
- 1998-12-02 ID IDW20001043A patent/ID24902A/id unknown
- 1998-12-02 CA CA002311731A patent/CA2311731A1/en not_active Abandoned
- 1998-12-02 JP JP2000522951A patent/JP4390030B2/ja not_active Expired - Lifetime
- 1998-12-02 EP EP98957141A patent/EP1050310A1/en not_active Withdrawn
-
1999
- 1999-05-26 TW TW088108677A patent/TW592716B/zh not_active IP Right Cessation
-
2000
- 2000-05-31 NO NO20002797A patent/NO20002797L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010032724A (ko) | 2001-04-25 |
JP4390030B2 (ja) | 2009-12-24 |
AU736407B2 (en) | 2001-07-26 |
NO20002797D0 (no) | 2000-05-31 |
CN1280507A (zh) | 2001-01-17 |
CA2311731A1 (en) | 1999-06-10 |
EP1050310A1 (en) | 2000-11-08 |
BR9815347A (pt) | 2000-10-10 |
WO1999027966A1 (fr) | 1999-06-10 |
NZ504825A (en) | 2001-11-30 |
AU1350799A (en) | 1999-06-16 |
ID24902A (id) | 2000-08-31 |
NO20002797L (no) | 2000-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW592716B (en) | Minoxidil-containing liquid composition | |
JP6244101B2 (ja) | ミノキシジル含有外用組成物 | |
TW477706B (en) | Skin tanning compositions and method | |
JPH02121906A (ja) | 化粧用組成物 | |
JP6199066B2 (ja) | ミノキシジル含有外用組成物 | |
JP2023099672A (ja) | 外用医薬組成物 | |
US3198708A (en) | Antiperspirant-deodorant composition | |
JPH1146849A (ja) | ミノキシジル配合育毛剤用容器 | |
JP6757130B2 (ja) | アズレン化合物を有する組成物、並びにアズレン化合物の変色防止剤及び変色防止方法 | |
JP2014214098A (ja) | ミノキシジル含有外用組成物 | |
JPH11263727A (ja) | ミノキシジル配合液剤組成物 | |
JP6880871B2 (ja) | エアゾール剤 | |
JP4189223B2 (ja) | ミノキシジル配合液剤組成物 | |
US3211620A (en) | Stabilized antiperspirant-deodorant composition | |
JP2564139B2 (ja) | 皮膚外用剤 | |
JP2018199738A (ja) | ミノキシジル含有外用組成物 | |
JP6769052B2 (ja) | タウリン含有組成物 | |
JP2017206558A (ja) | ミノキシジル含有外用組成物 | |
JP2017210480A (ja) | ミノキシジル含有外用組成物 | |
JP2007204489A (ja) | ミノキシジル配合育毛剤の着色防止方法 | |
JP5433142B2 (ja) | エアゾール剤 | |
JP2004155733A (ja) | 化粧品 | |
JP2005298452A (ja) | アズレン誘導体含有の水性液剤の安定化法 | |
JP2020172482A (ja) | 外用医薬組成物 | |
JP3672005B2 (ja) | 毛髪化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |